Related Experiment Video
Updated: Sep 23, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer
Midhun Malla1, Aparna R Parikh2
1Section of Hematology/Oncology, West Virginia University School of Medicine, 1 Medical Center Drive, Morgantown, WV 26506, USA.
Abstract:
This review provides a high level overview of several applications of circulating tumor DNA (ctDNA) in colorectal cancer (CRC) patients. ctDNA has been shown to be a promising prognostic biomarker for detection of minimal residual disease, monitoring for early recurrence and response monitoring in metastatic disease. Prospective studies are ongoing to investigate the ability of ctDNA to inform clinical decision making. This article also reviews existing and emerging alterations in CRC and their respective therapeutic approaches.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

